Nicox Overview
- Year Founded
-
1996
- Status
-
Public
- Employees
-
5
- Stock Symbol
-
ALCOX
- Investments
-
5
- Share Price
-
$0.32
- (As of Friday Closing)
Nicox General Information
Description
Nicox SA is an international ophthalmology company developing solutions to help preserve vision and improve ocular health. It is developing a portfolio of treatments targeting glaucoma, diseases of the anterior segment and retinal diseases. A drug candidate (NCX 470) in phase 3 clinical development designed to reduce intraocular pressure ("IOP") in patients with open-angle glaucoma or ocular hypertension. A drug candidate (NCX 1728) in preclinical development for retinal diseases and glaucoma, derived from Nicox's proprietary nitric oxide (NO)-donating research platform. Its products are ZERVIATE, VYZULTA, Naproxcinod, etc.
Contact Information
Website
www.nicox.comCorporate Office
- Sundesk Sophia Antipolis, Bâtiment C
- Emerald Square, rue Evariste Galois
- 06410 Biot
- France
Corporate Office
- Sundesk Sophia Antipolis, Bâtiment C
- Emerald Square, rue Evariste Galois
- 06410 Biot
- France
Nicox Timeline
Nicox Stock Performance
As of 13-Nov-2026, Nicox’s stock price is $0.32. Its current market cap is $31.3M with 98.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.32 | $0.32 | $0.31 - $0.67 | $31.3M | 98.8M | 144K | $0.10 |
Nicox Financials Summary
As of 30-Jun-2026, Nicox has a trailing 12-month revenue of $21.9M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 36,011 | 39,074 | 35,378 | 26,911 |
| Revenue | 21,918 | 18,918 | 8,504 | 7,470 |
| EBITDA | 36,483 | 25,932 | (6,947) | (22,579) |
| Net Income | 7,016 | (2,722) | (24,228) | (22,595) |
| Total Assets | 15,549 | 12,185 | 25,411 | 58,564 |
| Total Debt | 3,315 | 477 | 18,458 | 28,506 |
Nicox Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Nicox Comparisons
Industry
Financing
Details
Nicox Competitors (22)
One of Nicox’s 22 competitors is Kubota Vision, a Formerly VC-backed company based in Seattle, WA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Kubota Vision | Formerly VC-backed | Seattle, WA | ||||
| Pfizer (Vienna) | Corporation | Vienna, Austria | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA |
Nicox Patents
Nicox Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2024012261-A | Industrial process for preparation of hexanoic acid, 6-(nitrooxy)-, (1s,2e)-3-[(1r,2r,3s,5r)-2-[(2z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester and high pure product | Pending | 07-Jul-2022 | ||
| AU-2023303861-A1 | Industrial process for the preparation of hexanoic acid, 6-(nitrooxy)-, (1s,2e)-3-[(1r,2r,3s,5r)-2-[(2z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester and high pure product | Pending | 07-Jul-2022 | ||
| EP-4551553-A1 | Industrial process for the preparation of hexanoic acid, 6-(nitrooxy)-, (1s,2e)-3-[(1r,2r,3s,5r)-2-[(2z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester and high pure product | Pending | 07-Jul-2022 | ||
| US-12790291-B2 | Industrial process for the preparation of hexanoic acid, 6-(nitrooxy)-, (1s,2e)-3-[(1r,2r,3s,5r)-2-[(2z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester and high pure product | Active | 07-Jul-2022 | ||
| US-20240018096-A1 | Industrial process for the preparation of hexanoic acid, 6-(nitrooxy)-, (1s,2e)-3-[(1r,2r,3s,5r)-2-[(2z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester and high pure product | Active | 07-Jul-2022 | C07C405/0041 |
Nicox Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Nicox Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Nicox Investments & Acquisitions (5)
Nicox’s most recent deal was a Merger/Acquisition with Nicox Ophthalmics for . The deal was made on 28-Oct-2014.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Nicox Ophthalmics | 28-Oct-2014 | Merger/Acquisition | Drug Discovery | ||
| Doliage | 26-Sep-2014 | Merger/Acquisition | Laboratory Services (Healthcare) | ||
| AVEye Biotechnologie | 25-Sep-2014 | Merger/Acquisition | Other Healthcare Services | ||
| EuPharmed | 06-Dec-2013 | Merger/Acquisition | Pharmaceuticals | ||
| Altacor | 26-Mar-2012 | Later Stage VC | Pharmaceuticals |
Nicox ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Nicox Exits (1)
Nicox’s most recent exit was on 26-Mar-2012 from Altacor. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Altacor | 26-Mar-2012 | Completed |
|
Nicox FAQs
-
When was Nicox founded?
Nicox was founded in 1996.
-
Where is Nicox headquartered?
Nicox is headquartered in Biot, France.
-
What is the size of Nicox?
Nicox has 5 total employees.
-
What industry is Nicox in?
Nicox’s primary industry is Biotechnology.
-
Is Nicox a private or public company?
Nicox is a Public company.
-
What is Nicox’s stock symbol?
The ticker symbol for Nicox is ALCOX.
-
What is the current stock price of Nicox?
As of 13-Nov-2026 the stock price of Nicox is $0.32.
-
What is the current market cap of Nicox?
The current market capitalization of Nicox is $31.3M.
-
What is Nicox’s current revenue?
The trailing twelve month revenue for Nicox is $21.9M.
-
Who are Nicox’s competitors?
Kubota Vision, Pfizer (Vienna), Genetix Biotherapeutics, Immunocore Holdings, and Sarepta Therapeutics are some of the 22 competitors of Nicox.
-
What is Nicox’s annual earnings per share (EPS)?
Nicox’s EPS for 12 months was $0.10.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
